Application Filed for Dysuria Treatment KMD-3213 in China

Tokyo, January 8, 2009 – Daiichi Sankyo Company, Limited today announced that its subsidiary in China, Daiichi Pharmaceutical (Beijing) Co., Ltd. filed an application for KMD-3213 (generic name: silodosin) to China’s State Food and Drug Administration (SFDA). The drug was developed for treatment of dysuria associated with benign prostatic hyperplasia.

KMD-3213 is a selective alpha 1A-adrenoceptor antagonist originally discovered by Kissei Pharmaceutical Co., Ltd. It was developed by Daiichi Sankyo and Kissei Pharmaceutical and is jointly marketed as Urief® in Japan.

KMD-3213 has shown efficacy in significantly improving urinary disturbance soon after dosage and is expected to contribute to improving the quality of life in patients.